WT-1, BAALC, and ERG Expressions in Iranian Patients with Acute Myeloid Leukemia Pre- and Post-chemotherapy

Hossein Mehralizadeh ¹ , Mohammad Reza Aliparasti ², Mehdi Talebi ³, Shabnam Salekzamani ⁴, Shohreh Almasi ², Morteza Raeisi ⁵, Mehdi Yousefi ¹, AliAkbar Movassaghpour ⁵ *

Cited by CrossRef: 3

1- Kheirkhah A, Habibi S, Yousefi M, Mehri S, Ma B, Saleh M, Kavianpour M. Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia. Front Immunol. 2024;15 [Crossref]

2- Verma D, Kumar R, Ali M, Singh J, Arora M, Singh I, Kumari S, Bakhshi S, Sharma A, Palanichamy J, Tanwar P, Singh A, Chopra A. BAALC gene expression tells a serious patient outcome tale in NPM1-wild type/FLT3-ITD negative cytogenetically normal-acute myeloid leukemia in adults. Blood Cells, Molecules, and Diseases. 2022;95:102662 [Crossref]

3- Abo El Wafa R, Ahmed M, Ayad M, Ghallab O, Farghaly D. MECOM and BAALC gene expression profiles in Egyptian patients with acute myeloid leukemia by next generation sequencing. Alexandria Journal of Medicine. 2024;60(1):301 [Crossref]